Vitiligo – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Vitiligo – Pipeline Review, H2 2017’, provides an overview of the Vitiligo pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Vitiligo

The report reviews pipeline therapeutics for Vitiligo by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Vitiligo therapeutics and enlists all their major and minor projects

The report assesses Vitiligo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Vitiligo

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vitiligo

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Bristol-Myers Squibb Co

Celgene Corp

Clinuvel Pharmaceuticals Ltd

Incyte Corp

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Vitiligo - Overview 6

Vitiligo - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 9

Vitiligo - Therapeutics Assessment 10

Assessment by Target 10

Assessment by Mechanism of Action 12

Assessment by Route of Administration 14

Assessment by Molecule Type 16

Vitiligo - Companies Involved in Therapeutics Development 18

Aclaris Therapeutics Inc 18

Arrien Pharmaceuticals LLC 18

Bristol-Myers Squibb Co 19

Celgene Corp 20

Clinuvel Pharmaceuticals Ltd 20

Incyte Corp 21

Vitiligo - Drug Profiles 22

abatacept - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

afamelanotide - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

apremilast - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

ARN-4079 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

ATI-50001 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

ATI-50002 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

AX-1602 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ruxolitinib phosphate - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

VLRX-001 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Vitiligo - Dormant Projects 70

Vitiligo - Product Development Milestones 71

Featured News & Press Releases 71

Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study 71

Dec 03, 2015: Update on North American vitiligo program for SCENESSE 72

May 05, 2015: Clinuvel announces innovative melanocortin for new indications 73

Mar 20, 2015: SCENESSE vitiligo data presented at world’s largest dermatology conference 74

Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology 75

May 06, 2014: Clinuvel’s Phase II vitiligo study commences in Singapore 76

Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology 76

Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore 77

Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients 78

Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference 79

Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo 79

Oct 16, 2012: Observations from Clinuvels US vitiligo study published 80

Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the 81

Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial 82

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Tables

List of Tables

Number of Products under Development for Vitiligo, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Products under Development by Companies, H2 2017 9

Number of Products by Stage and Target, H2 2017 11

Number of Products by Stage and Mechanism of Action, H2 2017 13

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 17

Vitiligo – Pipeline by Aclaris Therapeutics Inc, H2 2017 18

Vitiligo – Pipeline by Arrien Pharmaceuticals LLC, H2 2017 18

Vitiligo – Pipeline by Bristol-Myers Squibb Co, H2 2017 19

Vitiligo – Pipeline by Celgene Corp, H2 2017 20

Vitiligo – Pipeline by Clinuvel Pharmaceuticals Ltd, H2 2017 20

Vitiligo – Pipeline by Incyte Corp, H2 2017 21

Vitiligo – Dormant Projects, H2 2017 70

List of Figures

List of Figures

Number of Products under Development for Vitiligo, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Top 10 Targets, H2 2017 10

Number of Products by Stage and Top 10 Targets, H2 2017 10

Number of Products by Top 10 Mechanism of Actions, H2 2017 12

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 12

Number of Products by Routes of Administration, H2 2017 14

Number of Products by Stage and Routes of Administration, H2 2017 14

Number of Products by Molecule Types, H2 2017 16

Number of Products by Stage and Molecule Types, H2 2017 16


Discounts available for multiple purchases.
+44 20 7947 2745

Saved reports